Following his presentation at ACR 2020, Rene Westhovens talked to us about the 52 week results of the FINCH 3 study. The phase 3 study evaluated the efficacy and safety of filgotinib in methotrexate-naïve patients with rheumatoid arthritis (Clinical Trial Identifier: NCT02886728). The abstract ‘Efficacy and Safety of Filgotinib in Methotrexate-Naïve Patients with Rheumatoid Arthritis: 52-Week Results’ (ABSTRACT NUMBER: 0217) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
Questions
- What were the 52-week findings from the FINCH-3 study? (0:39)
- What are your thoughts on the FDA rejecting filgotinib for moderate to severe active RA due to testicular toxicity? (4:00)
- If approved, where will filgotinib fit into the treatment paradigm for RA? (6:28)
Disclosures: Principal Investigator and Advisor for Celltrion and also Gilead/Galapagos
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
